31 maj: Skattereform: Ny kapitalpension er generationsrøveri til 150 mia...
03 jun: SimCorp på vej mod solid opjustering
01-06-2012 00:14:00

UK Regulator Draft Guidance Recommends Bayer's Xarelto For Blood Clots

Relateret indhold

FRANKFURT -(Dow Jones)- The U.K. drug regulator has recommended the use of Xarelto, a drug produced by a unit of Bayer AG (BAYN.XE), to treat blood clots, according to draft final guidance published Friday.

The guidance is likely to result in a recommendation from the National Institute for Health and Clinical Excellence, known as NICE, meaning the U.K. public health-care system will offer the drug and pay for it. The draft guidance is now with consultees, who have the opportunity to appeal against it.

"Bayer Healthcare welcomes this draft final appraisal determination recommendation from NICE because it simplifies the treatment of venous blood clot treatment for physicians and their patients," Bayer spokeswoman Astrid Kranz said.

Earlier, NICE had asked Bayer to provide more information on the drug. The move follows a May 22 approval for Xarelto for stroke prevention and systemic embolism in people with atrial fibrillation.

If the final approval is given, Xarelto, also known as Rivaroxaban, may then be offered as an alternative to injectable anticoagulants such as low-molecular-weight heparin or fondaparinux sodium, overlapped with a vitamin-K antagonist, such as warfarin.

It is estimated that there will be over 46,000 cases of acute deep vein thrombosis, or DVT, in England and Wales during 2012, rising to nearly 50,000 by 2016 due in large part to the aging population, NICE said.

"Xarelto is the first only novel oral anticoagulant offering a unique single drug solution for the treatment of DVT in adults," Kranz said.

On May 24, Bayer confirmed it expects peak sales of Xarelto of above EUR2 billion annually. The drug, which is being co-developed by Bayer and U.S. drug maker Johnson & Johnson (JNJ), is a rival of Boehringer Ingelheim GmbH's Pradaxa.

-By Monica Houston-Waesch, Dow Jones Newswires; +49 69 29 725 504; nikki.houston@dowjones.com

(END) Dow Jones Newswires

May 31, 2012 18:14 ET (22:14 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Moody's forudser indtjeningsvækst på 4-5 pct. i shippingmarkedet

18-06-2018 15:54:48
Udsigterne for det globale shippingmarked ser stabile ud for det næste års tid, vurderer kreditvurderingsinstituttet Moody's, som dog også spår forskelle i de enkelte undersegmenter. For tørlastsegmentet venter Moody's, at efterspørgslen vil overgå udbuddet med 1 pct. i 2018, mens der for containermarkedet ses en efterspørgsel, som vil være understøttet af bred makroøkonomisk vækst og handelsvækst..

Vestas-formand efter TDC-entre: Har ingen planer om at forlade Vestas

18-06-2018 12:00:37
Vestas' bestyrelsesformand siden 2012, Bert Nordberg, har ingen planer om at forlade den danske vindmølleproducent for at gøre plads til den formandspost hos TDC, som svenskeren tiltræder 1. august. Han erkender i et interview med Ritzau Finans dog, at det kan blive nødvendigt at skære ned på sine bestyrelsesposter. - Jeg overvejer det, men det er en drøftelse, jeg tager med nomineringskomitéerne ..

NKT/ABG: Falmende franske forventninger sender aktien ned

18-06-2018 09:37:04
Mandag morgen er det danske industrikabelselskab NKT røget ud af det fine selskab blandt eliteaktierne i det danske C25-indeks. Samtidig må selskabet se sin aktiekurs falde med 2,5 pct. til 191,10 kr. NKT kan nemlig skæve til den franske konkurrent Nexans, der venter en faldende indtjening i 2018, hvor driftsresultatet før af- og nedskrivninger ventes at lande på omkring 350 mio. euro, skriver Blo..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Nye C25-medlemmer, DSV og Vestas i fokus
2
Vestas/Sydbank: Regner med stærk afslutning på andet kvartal
3
KORR: Vestas: Modtager storordre på 442 MW i USA - GENT
4
Fingerprint Cards stiger en del efter chefers aktieopkøb
5
DSV/Morningstar: Sænker anbefalingen til "sælg"

Relaterede aktiekurser

Johnson & Johnson 121,32 -1,1% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
19. juni 2018 04:28:24
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180613.1 - EUROWEB3 - 2018-06-19 04:28:24 - 2018-06-19 04:28:24 - 1 - Website: OKAY